126 related articles for article (PubMed ID: 12702529)
1. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome.
Constans M; Sureda A; Terol MJ; Arranz R; Caballero MD; Iriondo A; Jarque I; Carreras E; Moraleda JM; Carrera D; León A; López A; Albó C; Díaz-Mediavilla J; Fernández-Abellán P; García-Ruiz JC; Hernández-Navarro F; Mataix R; Petit J; Pascual MJ; Rifón J; García-Conde J; Fernández-Rañada JM; Mateos MV; Sierra J; Conde E;
Ann Oncol; 2003 May; 14(5):745-51. PubMed ID: 12702529
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.
Sureda A; Arranz R; Iriondo A; Carreras E; Lahuerta JJ; García-Conde J; Jarque I; Caballero MD; Ferrà C; López A; García-Laraña J; Cabrera R; Carrera D; Ruiz-Romero MD; León A; Rifón J; Díaz-Mediavilla J; Mataix R; Morey M; Moraleda JM; Altés A; López-Guillermo A; de la Serna J; Fernández-Rañada JM; Sierra J; Conde E;
J Clin Oncol; 2001 Mar; 19(5):1395-404. PubMed ID: 11230484
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.
Sureda A; Constans M; Iriondo A; Arranz R; Caballero MD; Vidal MJ; Petit J; López A; Lahuerta JJ; Carreras E; García-Conde J; García-Laraña J; Cabrera R; Jarque I; Carrera D; García-Ruiz JC; Pascual MJ; Rifón J; Moraleda JM; Pérez-Equiza K; Albó C; Díaz-Mediavilla J; Torres A; Torres P; Besalduch J; Marín J; Mateos MV; Fernández-Rañada JM; Sierra J; Conde E;
Ann Oncol; 2005 Apr; 16(4):625-33. PubMed ID: 15737986
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.
Nademanee A; Molina A; Fung H; Stein A; Parker P; Planas I; O'Donnell MR; Snyder DS; Kashyap A; Spielberger R; Bhatia R; Krishnan A; Sniecinski I; Vora N; Slovak M; Dagis A; Niland JC; Forman SJ
Biol Blood Marrow Transplant; 1999; 5(5):292-8. PubMed ID: 10534059
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
Rodríguez J; Caballero MD; Gutiérrez A; Marín J; Lahuerta JJ; Sureda A; Carreras E; León A; Arranz R; Fernández de Sevilla A; Zuazu J; García-Laraña J; Rifon J; Varela R; Gandarillas M; SanMiguel J; Conde E
Ann Oncol; 2003 Dec; 14(12):1768-75. PubMed ID: 14630683
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
7. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C
J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
[TBL] [Abstract][Full Text] [Related]
8. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Canals C; Arranz R; Caballero D; Ribera JM; Brune M; Passweg J; Martino R; Valcárcel D; Besalduch J; Duarte R; León A; Pascual MJ; García-Noblejas A; López Corral L; Xicoy B; Sierra J; Schmitz N
Haematologica; 2012 Feb; 97(2):310-7. PubMed ID: 21993674
[TBL] [Abstract][Full Text] [Related]
11. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH
J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605
[TBL] [Abstract][Full Text] [Related]
12. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registry.
Moreau P; Fleury J; Brice P; Colombat P; Bouabdallah R; Lioure B; Voillat L; Casasnovas O; François S; Sadoun A; Lamy T; Lotz JP; Munck JN; Divine M; Fermé C; Pény AM; Fruchart C; Oriol P; Ojeda M; Reman O; Milpied N; Gisselbrecht C; Legros M; Harousseau JL
Bone Marrow Transplant; 1998 Apr; 21(8):787-93. PubMed ID: 9603402
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
[TBL] [Abstract][Full Text] [Related]
14. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
15. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
[TBL] [Abstract][Full Text] [Related]
16. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.
Czyz J; Dziadziuszko R; Knopinska-Postuszuy W; Hellmann A; Kachel L; Holowiecki J; Gozdzik J; Hansz J; Avigdor A; Nagler A; Osowiecki M; Walewski J; Mensah P; Jurczak W; Skotnicki A; Sedzimirska M; Lange A; Sawicki W; Sulek K; Wach M; Dmoszynska A; Kus A; Robak T; Warzocha K
Ann Oncol; 2004 Aug; 15(8):1222-30. PubMed ID: 15277262
[TBL] [Abstract][Full Text] [Related]
17. [Autologous stem cell transplantation in the treatment of Hodgkin's disease].
Tarabar O; Tukić L; Stamatović D; Balint B; Elez M; Ostojić G; Tatomirović Z; Marjanović S
Vojnosanit Pregl; 2009 Jul; 66(7):571-6. PubMed ID: 19678583
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Caballero MD; Pérez-Simón JA; Iriondo A; Lahuerta JJ; Sierra J; Marín J; Gandarillas M; Arranz R; Zuazu J; Rubio V; Fernández de Sevilla A; Carreras E; García-Conde J; García-Laraña J; Grande C; Sureda A; Vidal MJ; Rifón J; Pérez-Equiza C; Varela R; Moraleda JM; García Ruíz JC; Albó C; Cabrera R; San Miguel JF; Conde E
Ann Oncol; 2003 Jan; 14(1):140-51. PubMed ID: 12488306
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
Sureda A; Mataix R; Hernández-Navarro F; Jarque I; Lahuerta JJ; Tomás JF; Brunet S; Caballero D; Conde E; León A; Fernández MN; López A; Maldonado J; Bengoechea E; Callís M; Carrera D; García-Conde J; García-Laraña J; Moraleda JM; Morey M; Rifón J; Sierra J; Torres A; Domingo-Albós A
Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
